Fabry Disease Is Rare But Very Serious

Fabry disease is a rare inherited disorder of glycosphingolipid (fat) metabolism resulting from the absent or markedly deficient activity of the lysosomal enzyme, a-galactosidase A (a-Gal A). This disorder belongs to a group of diseases known as lysosomal storage disorders. This enzymatic deficiency is caused by alterations (mutations) in the a-galactosidase A (GLA) gene that instructs cells to make the a-galactosidase A (a-Gal A) enzyme. Lysosomes function as the primary digestive tract of cells. Enzymes within lysosomes break down or digest particular compounds and intracellular structures. a-Gal A functions to break down complex sugar-lipid molecules called glycolipids, specifically, globotriaosylceramide (GL-3 or Gb3), its deacylated form Lyso-GL-3/Gb3 and related glycolipids, by removing the terminal galactose sugar from the end of these glycolipid molecules.

Cause and Genetics

Fabry disease is caused by mutations in the GLA gene, which provides instructions for making an enzyme called alpha-galactosidase A. This enzyme is responsible for breaking down GL-3 in the lysosomes — the "recycling centers" of cells. When the enzyme is deficient or nonfunctional, GL-3 accumulates in tissues throughout the body, leading to cellular damage.

The condition is X-linked, meaning the defective gene is located on the X chromosome. Since males have only one X chromosome, they are typically more severely affected. Females have two X chromosomes, so they may be asymptomatic carriers or have milder symptoms, though some can be seriously affected as well.

Signs and Symptoms

Symptoms of Fabry disease often begin in childhood or adolescence, although the severity and age of onset can vary significantly. Common early symptoms include:
Burning pain in the hands and feet (acroparesthesias)

Heat and cold intolerance

Decreased sweating (anhidrosis or hypohidrosis)
Angiokeratomas (small, dark red skin spots, often on the lower trunk)
Corneal clouding (seen on eye exam, usually without vision problems)
Gastrointestinal issues, such as abdominal pain, bloating, or diarrhea
As the disease progresses, organ damage becomes more apparent, especially in the kidneys, heart, and brain:
Kidneys: Proteinuria, progressive loss of kidney function, leading to kidney failure
Heart: Left ventricular hypertrophy, arrhythmias, heart failure
Brain: Increased risk of stroke or transient ischemic attacks (TIAs), even in young adults.

 Type of Fabry Disease

There are two main clinical forms:

Classic Fabry Disease: Typically affects males and presents in childhood or adolescence with a full spectrum of symptoms.
Late-onset (atypical) Fabry Disease: Often affects adults, with more isolated symptoms, such as only cardiac or renal involvement.
This variation in presentation can make diagnosis difficult and may delay appropriate treatment.

Diagnosis

Diagnosing Fabry disease can be challenging due to its rarity and the wide range of symptoms. A combination of clinical evaluation, family history, and specialized tests is used, including:

Enzyme assay: Measures alpha-galactosidase A activity in blood or cells. Low or absent levels confirm diagnosis in males.
Genetic testing: Identifies mutations in the GLA gene, particularly useful for confirming diagnosis in females and family screening.
Tissue biopsy and urine tests may also be used to detect GL-3 buildup.
Early diagnosis is critical, as treatment is more effective when started before irreversible damage occurs.

Treatment Options

There is no cure for Fabry disease, but several treatment options can significantly improve quality of life and slow disease progression:
Enzyme Replacement Therapy (ERT): Involves intravenous infusion of synthetic alpha-galactosidase A every two weeks. Two ERT drugs are commonly used: agalsidase beta and agalsidase alfa. ERT can reduce GL-3 accumulation and improve organ function over time.

Chaperone Therapy: An oral medication called migalastat is suitable for patients with specific GLA mutations. It helps stabilize the faulty enzyme, allowing it to function more effectively.

Supportive Care: Management of symptoms and complications includes:
Pain medications (neuropathic pain)
Blood pressure control (especially in kidney disease)
Dialysis or kidney transplant if renal failure occurs
Cardiac medications or interventions (pacemaker, defibrillator)
Stroke prevention strategies
Gene Therapy (Experimental): Emerging therapies aim to correct the underlying genetic defect, offering the possibility of a long-term cure. Clinical trials are ongoing.

Fabry disease is a lifelong condition that requires multidisciplinary care, including nephrologists, cardiologists, neurologists, geneticists, and pain specialists. Psychological support is also important, as chronic illness can take a toll on mental health.

Family screening and genetic counseling are crucial because Fabry disease is inherited. Early detection in relatives can lead to timely intervention and better outcomes.

Fabry disease may be rare, but its impact on individuals and families is profound. With early recognition, accurate diagnosis, and ongoing treatment, many patients can manage their symptoms and lead fulfilling lives. As research continues to evolve, the future holds promise for more effective and accessible therapies.


SMM Musabbir Uddin is a student of 
Universal Medical College, Dhaka.